The field of internal medicine is evolving at unprecedented speed and humankind is steadily growing older. Progress in diagnostics and treatment have improved the prognosis of many diseases and led to chronicity of previous killer entities. A fair part of this pleasing trend is attributable to the field of oncology that, within the last 20 years, unearthed a plethora of medicines with novel modes-of-action and/or innovative enabling technology, including therapeutic antibodies and small molecule inhibitors.
